Skip to main content

Table 1 Main characteristics of the selected studies

From: The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials

Citation Mean age (years) Number of patients Duration of follow up (month) Dose and frequency of crizotinib administration Trial phase Tumor histologic type (Adenocarcinoma, %) Extent of disease (Metastatic, %)
Shaw et al. [21] 50.0 173 12.2 250 mg twice daily Phase 3 95 95
Brosnan et al. [22] 54.7 38 16.3 250 mg twice daily NA NA NA
Riely [23] 53.0 261 12.0 250 mg twice daily Phase 2 92 NA
Camidge et al. [19] 52.0 149 16.3 250 mg twice daily Phase 1 97 NA
Shaw et al. [20] 51.0 56 18.0 250 mg twice daily Phase 1 96 89
Kwak et al. [14] 51.0 82 6.4 250 mg twice daily Phase 1 96 NA
  1. NA = not applicable.
\